A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy

Abstract Immune checkpoint blockade (ICB) has become a standard anti-cancer treatment, offering durable clinical benefits. However, the limited response rate of ICB necessitates biomarkers to predict and modulate the efficacy of the therapy. The gut microbiome’s influence on ICB efficacy is of parti...

Full description

Saved in:
Bibliographic Details
Main Authors: Chan Yeong Kim, Dong Jin Park, Beung Chul Ahn, Seungbyn Baek, Min Hee Hong, Linh Thanh Nguyen, Sun Ha Hwang, Nayeon Kim, Daniel Podlesny, Askarbek Orakov, Christian Schudoma, Shahriyar Mahdi Robbani, Hyo Sup Shim, Hong In Yoon, Chang Young Lee, Seong Yong Park, Dongeun Yong, Mina Han, Peer Bork, Byoung Choul Kim, Sang-Jun Ha, Hye Ryun Kim, Insuk Lee
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-55388-3
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850102994138300416
author Chan Yeong Kim
Dong Jin Park
Beung Chul Ahn
Seungbyn Baek
Min Hee Hong
Linh Thanh Nguyen
Sun Ha Hwang
Nayeon Kim
Daniel Podlesny
Askarbek Orakov
Christian Schudoma
Shahriyar Mahdi Robbani
Hyo Sup Shim
Hong In Yoon
Chang Young Lee
Seong Yong Park
Dongeun Yong
Mina Han
Peer Bork
Byoung Choul Kim
Sang-Jun Ha
Hye Ryun Kim
Insuk Lee
author_facet Chan Yeong Kim
Dong Jin Park
Beung Chul Ahn
Seungbyn Baek
Min Hee Hong
Linh Thanh Nguyen
Sun Ha Hwang
Nayeon Kim
Daniel Podlesny
Askarbek Orakov
Christian Schudoma
Shahriyar Mahdi Robbani
Hyo Sup Shim
Hong In Yoon
Chang Young Lee
Seong Yong Park
Dongeun Yong
Mina Han
Peer Bork
Byoung Choul Kim
Sang-Jun Ha
Hye Ryun Kim
Insuk Lee
author_sort Chan Yeong Kim
collection DOAJ
description Abstract Immune checkpoint blockade (ICB) has become a standard anti-cancer treatment, offering durable clinical benefits. However, the limited response rate of ICB necessitates biomarkers to predict and modulate the efficacy of the therapy. The gut microbiome’s influence on ICB efficacy is of particular interest due to its modifiability through various interventions. However, gut microbiome biomarkers for ICB response have been inconsistent across different studies. Here, we identify TANB77, an uncultured and distinct bacterial clade, as the most consistent responder-enriched taxon through meta-analysis of ten independent ICB recipient cohorts. Traditional taxonomy fails to distinguish TANB77 from unrelated taxa, leading to its oversight. Mice with higher gut TANB77 abundance, either naturally or through transplantation, show improved response to anti-PD-1 therapy. Additionally, mice injected with TANB77-derived pilin-like protein exhibit improved anti-PD-1 therapy response, providing in vivo evidence for the beneficial role of the pilin-like protein. These findings suggest that pilins from the TANB77 order may enhance responses to ICB therapy across diverse cohorts of cancer patients.
format Article
id doaj-art-343a89effa8d4c65b8cf8813b8a50d9f
institution DOAJ
issn 2041-1723
language English
publishDate 2024-12-01
publisher Nature Portfolio
record_format Article
series Nature Communications
spelling doaj-art-343a89effa8d4c65b8cf8813b8a50d9f2025-08-20T02:39:38ZengNature PortfolioNature Communications2041-17232024-12-0115111910.1038/s41467-024-55388-3A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapyChan Yeong Kim0Dong Jin Park1Beung Chul Ahn2Seungbyn Baek3Min Hee Hong4Linh Thanh Nguyen5Sun Ha Hwang6Nayeon Kim7Daniel Podlesny8Askarbek Orakov9Christian Schudoma10Shahriyar Mahdi Robbani11Hyo Sup Shim12Hong In Yoon13Chang Young Lee14Seong Yong Park15Dongeun Yong16Mina Han17Peer Bork18Byoung Choul Kim19Sang-Jun Ha20Hye Ryun Kim21Insuk Lee22Department of Biotechnology, College of Life Science and Biotechnology, Yonsei UniversityBrain Korea 21 (BK21) FOUR Program, Yonsei Education & Research Center for Biosystems, Yonsei UniversityDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of MedicineDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei UniversityDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of MedicineDepartment of Nano-bioengineering, Incheon National UniversityDepartment of Nano-bioengineering, Incheon National UniversityDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei UniversityEuropean Molecular Biology Laboratory, Molecular Systems Biology UnitEuropean Molecular Biology Laboratory, Molecular Systems Biology UnitEuropean Molecular Biology Laboratory, Molecular Systems Biology UnitEuropean Molecular Biology Laboratory, Molecular Systems Biology UnitDepartment of Pathology, Yonsei University College of MedicineDepartment of Radiation Oncology, Yonsei University College of MedicineDepartment of Thoracic and Cardiovascular Surgery, Yonsei University College of MedicineDepartment of Thoracic and Cardiovascular Surgery, Yonsei University College of MedicineDepartment of Laboratory Medicine, Research Institute of Bacterial Resistance, Yonsei University College of MedicineDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of MedicineEuropean Molecular Biology Laboratory, Molecular Systems Biology UnitDepartment of Nano-bioengineering, Incheon National UniversityBrain Korea 21 (BK21) FOUR Program, Yonsei Education & Research Center for Biosystems, Yonsei UniversityDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of MedicineDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei UniversityAbstract Immune checkpoint blockade (ICB) has become a standard anti-cancer treatment, offering durable clinical benefits. However, the limited response rate of ICB necessitates biomarkers to predict and modulate the efficacy of the therapy. The gut microbiome’s influence on ICB efficacy is of particular interest due to its modifiability through various interventions. However, gut microbiome biomarkers for ICB response have been inconsistent across different studies. Here, we identify TANB77, an uncultured and distinct bacterial clade, as the most consistent responder-enriched taxon through meta-analysis of ten independent ICB recipient cohorts. Traditional taxonomy fails to distinguish TANB77 from unrelated taxa, leading to its oversight. Mice with higher gut TANB77 abundance, either naturally or through transplantation, show improved response to anti-PD-1 therapy. Additionally, mice injected with TANB77-derived pilin-like protein exhibit improved anti-PD-1 therapy response, providing in vivo evidence for the beneficial role of the pilin-like protein. These findings suggest that pilins from the TANB77 order may enhance responses to ICB therapy across diverse cohorts of cancer patients.https://doi.org/10.1038/s41467-024-55388-3
spellingShingle Chan Yeong Kim
Dong Jin Park
Beung Chul Ahn
Seungbyn Baek
Min Hee Hong
Linh Thanh Nguyen
Sun Ha Hwang
Nayeon Kim
Daniel Podlesny
Askarbek Orakov
Christian Schudoma
Shahriyar Mahdi Robbani
Hyo Sup Shim
Hong In Yoon
Chang Young Lee
Seong Yong Park
Dongeun Yong
Mina Han
Peer Bork
Byoung Choul Kim
Sang-Jun Ha
Hye Ryun Kim
Insuk Lee
A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy
Nature Communications
title A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy
title_full A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy
title_fullStr A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy
title_full_unstemmed A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy
title_short A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy
title_sort conserved pilin from uncultured gut bacterial clade tanb77 enhances cancer immunotherapy
url https://doi.org/10.1038/s41467-024-55388-3
work_keys_str_mv AT chanyeongkim aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT dongjinpark aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT beungchulahn aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT seungbynbaek aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT minheehong aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT linhthanhnguyen aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT sunhahwang aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT nayeonkim aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT danielpodlesny aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT askarbekorakov aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT christianschudoma aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT shahriyarmahdirobbani aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT hyosupshim aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT honginyoon aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT changyounglee aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT seongyongpark aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT dongeunyong aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT minahan aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT peerbork aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT byoungchoulkim aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT sangjunha aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT hyeryunkim aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT insuklee aconservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT chanyeongkim conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT dongjinpark conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT beungchulahn conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT seungbynbaek conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT minheehong conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT linhthanhnguyen conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT sunhahwang conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT nayeonkim conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT danielpodlesny conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT askarbekorakov conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT christianschudoma conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT shahriyarmahdirobbani conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT hyosupshim conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT honginyoon conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT changyounglee conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT seongyongpark conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT dongeunyong conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT minahan conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT peerbork conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT byoungchoulkim conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT sangjunha conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT hyeryunkim conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy
AT insuklee conservedpilinfromunculturedgutbacterialcladetanb77enhancescancerimmunotherapy